• Michael M Morgan, Erin N Fossum, Carly S Levine, and Susan L Ingram.
• Department of Psychology, Washington State University Vancouver, Vancouver, WA 98686, USA. morgan@vancouver.wsu.edu
• Pharmacol. Biochem. Behav. 2006 Sep 1;85(1):214-9.

AbstractThe periaqueductal gray (PAG) appears to play a key role in morphine antinociception and tolerance. The objective of this manuscript is to develop a cumulative dose microinjection procedure so the hypothesized role of the PAG in morphine antinociceptive tolerance can be assessed using dose-response analysis. Rats were implanted with a guide cannula into the ventrolateral PAG. Microinjection of cumulative half log doses of morphine (0.32, 1, 3.2, and 10 micro g/0.4 micro l) produced antinociception on the hot plate test only at the two highest doses. Microinjection of quarter log doses of morphine into the PAG (1, 1.8, 3.2, 5.6, and 10 micro g/0.4 micro l) resulted in an ED(50) for antinociception of 1.8 mug. Systemic administration of the opioid antagonist naloxone increased the morphine ED(50) to 9.0 micro g. Repeated microinjections of saline into the PAG had no effect on nociception. Pretreatment with twice daily injections of morphine, either systemically (5 mg/kg, s.c.) or into the PAG (5 micro g/0.4 micro l), for 2 days produced a two-fold increase in the ED(50) for morphine antinociception. These data validate the use of an intracranial cumulative dose procedure to assess morphine potency and demonstrate that microinjection of morphine into the PAG is sufficient to produce tolerance.

12 keywords...

hide…